Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06273124
Other study ID # 150-1261-00
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 7, 2024
Est. completion date January 15, 2025

Study information

Verified date April 2024
Source Tandem Diabetes Care, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS). Participants will be asked to: 1. Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods 2. Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour


Description:

This is a multi-center, single-arm, prospective study of an extended wear infusion set in adults with Type 1 diabetes using a Tandem t:slim X2 insulin pump with Control-IQ technology with continuous Glucose Monitoring (CGM). Up to 300 participants across the United States age 18-80 will be enrolled in up to 20 investigational centers. Participants will change insulin cartridge every 48 to 72 hours as recommended by their health care provider. Participants will be expected to participate in the study for approximately 12-16 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 260
Est. completion date January 15, 2025
Est. primary completion date January 15, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Inclusion Criteria: 1. Age 18 to 80 years old inclusive 2. Generally in good health, as determined by the investigator 3. Living in the United States with no plans to move outside the United States during the study 4. Diagnosis of T1D for at least 12 months 5. Minimum of 6 months of insulin pump experience and at least 3 months of current experience with a Tandem pump 6. Using Tandem t:slim X2 insulin pump with Control-IQ technology for a minimum of 1 month at the time of enrollment 7. Minimum of 14 days of Control-IQ data immediately preceding screening that demonstrate pump use compliance, including at least 85% of time with Control-IQ technology active 8. HbA1c <9.0% in the last 6 months. 9. Willing to implement and adhere to pump alert/alarm settings on a study-provided pump as instructed during the study 10. Willing to wear each investigational infusion set for up to 7 days during each of the 12 consecutive wear periods in the study 11. Willing to perform blood ketone and blood glucose (fingerstick) measurements as directed using provided ketone and blood glucose meters and strips 12. Access to internet for required periodic uploads of study device data 13. BMI in the range 18-35 kg/m2, both inclusive 14. Currently using one of the following insulins with no expectation of a need to change insulin type during the study: 1. Humalog™* (insulin lispro) 2. NovoLog™* (insulin aspart) 15. Using Humalog™ insulin lispro or NovoLog™ insulin aspart for a minimum of 1 month at the time of enrollment 16. Willing to change insulin cartridge every 48-72 hours, as recommended by patient's healthcare provider during the study 17. Has routine access to a smart phone e.g., ability to receive text messages 18. Has the ability to understand and comply with protocol procedures and to provide informed consent (i.e., English proficient in both verbal and written communication) Exclusion Criteria: 1. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas) 2. Female subject is pregnant, planning to become pregnant, or not using adequate method of contraception 3. Episodes of severe hypoglycemia in the last 6 months resulting in: 1. Medical Assistance (i.e., paramedics, hospital evaluation or hospitalization) 2. Loss of consciousness 3. Seizures 4. One or more episodes of diabetic ketoacidosis (DKA) in the last 6 months requiring hospitalization 5. Currently on a ketogenic or low-carbohydrate diet of less than 60 grams of carbohydrates per day, or intending to begin one during the study period 6. Known cardiovascular disease considered to be clinically relevant by the investigator 7. Known history of any of the following conditions: 1. Cushing's Disease 2. Pancreatic islet cell tumor 3. Insulinoma 4. Lipodystrophy 5. Extensive lipohypertrophy, as assessed by the investigator 8. Currently undergoing treatment with: 1. Systemic oral or intravenous corticosteroids (current or within the last 8 weeks from screening), 2. Thyroid hormones, unless use has been stable during the past 3 months 9. Significant history of any of the following, that in the opinion of the investigator would compromise safety or successful study participation: 1. Alcoholism 2. Drug abuse 10. Significant acute or chronic illness, that in the opinion of the investigator might interfere with safety or integrity of study results 11. Current participation in another clinical drug or device study 12. Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is a study site personnel directly affiliated with this study or who is an employee of Capillary Biomedical

Study Design


Intervention

Device:
SteadiSet Extended Wear Infusion Set
Each participant will be given 12 Extended Wear Infusion Sets to wear over 12 wear periods up to 168 hours each.

Locations

Country Name City State
United States Barbara Davis Center Aurora Colorado
United States Texas Diabetes and Endocrinology Austin Texas
United States Massachusetts General Hospital Boston Massachusetts
United States Henry Ford Health System Detroit Michigan
United States Northwestern University Evanston Illinois
United States Rocky Mountain Clinical Research Idaho Falls Idaho
United States International Diabetes Center - HealthPartners Institute Minneapolis Minnesota
United States Icahn School of Medicine at Mt. Sinai New York New York
United States Hoag Memorial Hospital Presbyterian Newport Beach California
United States Rainier Clinical Research Center Renton Washington
United States Mayo Clinic Rochester Minnesota
United States Endocrine Research Solutions Roswell Georgia
United States University of Washington Seattle Washington
United States Stanford University Stanford California
United States SUNY Upstate Medical University Syracuse New York

Sponsors (2)

Lead Sponsor Collaborator
Tandem Diabetes Care, Inc. Jaeb Center for Health Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Outcome Measure Rate of infusion set failure at the end of 7 days in participants taking Novolog 168 hours
Primary Primary Outcome Rate of infusion set failure at the end of 7 days in participants taking Humalog 168 hours
See also
  Status Clinical Trial Phase
Completed NCT03886974 - Transition to Adult Care in Type 1 Diabetes
Completed NCT05620251 - Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Active, not recruiting NCT05078658 - Low-carbohydrate Diet in Children With Type 1 Diabetes N/A
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Completed NCT03177096 - Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes N/A
Not yet recruiting NCT06418269 - The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes N/A
Completed NCT04172077 - Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
Recruiting NCT04950634 - Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Completed NCT04450745 - Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients N/A
Completed NCT03165786 - A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes N/A
Terminated NCT04028960 - IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase Phase 2
Recruiting NCT05324488 - Diabetes Registry Graz for Biomarker Research
Completed NCT02984709 - Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes N/A
Completed NCT02984514 - Brown Adipose Tissue in Type 1 Diabetes N/A
Recruiting NCT06372392 - Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps N/A
Recruiting NCT05973799 - Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes N/A
Recruiting NCT03311516 - New Insulin Therapy by Multiwave Bolus N/A
Completed NCT03711656 - Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques N/A